The Q2 miss is material for a $15M market cap company. The retina business weakness is structural (regulatory delays, international disruptions), not temporary. While glaucoma growth is strong, it cannot offset the larger retina decline. The reaffirmed guidance implies a back-half-weighted recovery that now seems stretched given Q1 and Q2 revenue of $11.8M and $12.6M (total $24.4M) vs the $51M-$53M target, requiring $26.6M-$28.6M in H2. Monitor the Q3 2026 earnings for retina recovery signs and cash burn trajectory; the planned inventory build for the headquarters move could pressure liquidity further.
Price Chart
Executive Summary
Iridex reported Q2 2026 revenue of $12.6M, a 7% YoY decline from $13.6M, missing the $13.6M consensus. EPS of -$0.07 was a 600% miss vs the -$0.01 estimate. The revenue decline was driven by a sharp drop in retina product sales ($6.5M vs $8.0M YoY), partially offset by 19% growth in Cyclo G6 glaucoma probe revenue. The company reaffirmed its full-year 2026 revenue guidance of $51M-$53M, but the worsening net loss (-$1.3M vs -$1.0M YoY) and negative adjusted EBITDA (-$0.4M vs +$21K) signal deteriorating profitability.
Key Financial Metrics
Key Facts
- Total revenue of $12.6M declined 7% YoY from $13.6M, missing the $13.6M consensus estimate.
- GAAP EPS of -$0.07 missed the -$0.01 consensus by 600% and worsened from -$0.06 in Q2 2025.
- Retina product revenue fell 19% to $6.5M from $8.0M YoY, due to Middle East disruptions and China sell-through issues.
- Cyclo G6 product family revenue grew 19% to $3.9M, driven by a 35% increase in probe volume (17,700 vs 13,100).
- Gross margin was essentially flat at 34.2% vs 34.5% in the prior year period.
- Operating expenses decreased 5% to $5.3M, but the net loss widened to $1.3M from $1.0M.
- Adjusted EBITDA turned negative at -$0.4M vs +$21K in Q2 2025.
- Cash and cash equivalents were $4.7M, a slight increase of $0.1M from Q1 2026.
- Full-year 2026 revenue guidance reaffirmed at $51M-$53M, but cash flow outlook updated to include working capital use for inventory build ahead of headquarters relocation.
- The company is restructuring, including transferring production to lower-cost contract manufacturers and relocating headquarters.
Financial Impact
Revenue miss of $1.0M (7.4% below consensus) and EPS miss of $0.06 (600% below consensus). Net loss widened by $0.3M YoY. Adjusted EBITDA swung from +$21K to -$0.4M.
Risk Factors
- Continued weakness in retina product sales due to international regulatory delays and Middle East/China disruptions.
- Cash burn risk: with only $4.7M cash and a widening net loss, the company may need to raise capital if the H2 revenue ramp falls short.
- Execution risk on the restructuring (manufacturing transfer, headquarters relocation) could disrupt supply chains and delay regulatory approvals.
- The $51M-$53M full-year guidance implies a significant H2 acceleration that may be unachievable given H1 revenue of $24.4M.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-355635 |
| Document: irix-20260818.htm | 0001193125-26-355635 |
| Document: 0001193125-26-355635-index-headers.html | 0001193125-26-355635 |
| Document: 0001193125-26-355635-index.html | 0001193125-26-355635 |
| Document: 0001193125-26-355635.txt | 0001193125-26-355635 |
| 8-K Data (Synthetic) | 0001193125-26-355635 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 18, 2026 10w ago | 8-K | $0.7829 $0.6517 | ▲ +16.76% | ▲ +14.81% | $0.7400 (+5.48%) |
Aug 18, 2026 10w ago | Press Release | $0.7829 $0.6517 | ▲ +16.76% | ▲ +14.81% | $0.7400 (+5.48%) |
Jul 16, 2026 14w ago | 8-K | $0.9510 $0.8241 | ▲ +13.34% | ▲ +16.96% | $0.7400 (+22.19%) |
May 19, 2026 23w ago | 8-K | $1.00 $1.13 | ▲ +13.00% | ▲ +12.26% | $0.7400 (−26.00%) |
Apr 24, 2026 26w ago | DEFA14A | $1.08 $1.04 | ▼ −3.70% | ▼ −8.66% | $0.7400 (−31.48%) |
Apr 7, 2026 29w ago | Press Release | $1.03 $1.05 | ▲ +1.94% | ▼ −6.60% | $0.7400 (−28.16%) |
Mar 26, 2026 30w ago | Press Release | $0.9900 $1.08 | ▲ +9.09% | ▼ −3.65% | $0.7400 (−25.25%) |
Mar 12, 2026 32w ago | Press Release | $1.30 $1.03 | ▼ −20.77% | ▼ −24.36% | $0.7400 (−43.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers